chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Cardiac failure congestive, Chest X-ray normal, Computerised tomogram head, Echocardiogram
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 2/23/21 (EN6200) Pfizer Dose 2 3/17/21 (EN6204) COVID Positive 12/7/21 COVID Positive 12/16/21  12/7/21: A 90-year-old woman with a history of hypertension, colonic diverticulosis who presented to the emergency room with complains left-sided facial facial droop and weakness which was noticed today.  Family had noted weakness in the right upper extremity.  No prior history of stroke.  No history of coronary artery disease. No loss of consciousness.  On presentation to the emergency room, vital signs revealed elevated blood pressure with systolic of 184/80 mmHg.  Laboratory workup is unremarkable.  EKG done reveals sinus rhythm with first-degree AV block with supraventricular complexes. Chest x-ray reveals no acute abnormality.  CT scan of the head does not reveal any acute intracranial process which shows bilateral chronic use to me changes.  In the emergency room patient received aspirin neurologist was consulted who recommended admission to the hospitalist service.  Patient is being admitted to the hospitalist service to rule out CVA  12/17/21: Possible TIA  - with gait instability. MRI brain: no acute infarct. Currently on aspirin and high-intensity statin.  No focal deficits appreciated during course of exam.  Patient appears to be baseline continue meds as ordered optimize blood pressures noted below.  COVID-19 infection  - with intermittent fever, but no respiratory symptoms. Continues to be on room air, remains afebrile for greater than 24 hours.  Mild leukopenia, trend.  Chest x-ray negative CRP 2.5.   Supportive measures currently. COVID-19 precautions to be provided for dispo.  suspected acute bronchitis: improved clinically  - did receive short course of antibiotics no coughing congestion or coarse sounds noted room air symptomatic management as noted will need to mobilize Acapella.  Uncontrolled hypertension: improved  - On  BP meds: Atenolol, Losartan, Isosorbide, Hydralazine.  Does periodically have some high readings, medications have been titrated.  Suspect may need further titration have strongly advised to follow-up with PCP within 7 days of discharge from skilled for further management titration of blood pressure.  chronic systolic dysfunction- CHF-not in acute exacerbation  - Echo: EF:35-45% On Atenolol and Losartan.  Continue monitor fluid status  Deconditioning with gait instability  PT/OT. social service for placement to SNF when bed is available    All ED in RTC precautions have been provided patient, she endorses understanding and is agreement with plan as outlined.  She patient will need to follow PCP within 7 days of discharge for longitudinal management.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Ejection fraction, Electrocardiogram abnormal, Facial paralysis, Gait disturbance, Hypertension
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 2/23/21 (EN6200) Pfizer Dose 2 3/17/21 (EN6204) COVID Positive 12/7/21 COVID Positive 12/16/21  12/7/21: A 90-year-old woman with a history of hypertension, colonic diverticulosis who presented to the emergency room with complains left-sided facial facial droop and weakness which was noticed today.  Family had noted weakness in the right upper extremity.  No prior history of stroke.  No history of coronary artery disease. No loss of consciousness.  On presentation to the emergency room, vital signs revealed elevated blood pressure with systolic of 184/80 mmHg.  Laboratory workup is unremarkable.  EKG done reveals sinus rhythm with first-degree AV block with supraventricular complexes. Chest x-ray reveals no acute abnormality.  CT scan of the head does not reveal any acute intracranial process which shows bilateral chronic use to me changes.  In the emergency room patient received aspirin neurologist was consulted who recommended admission to the hospitalist service.  Patient is being admitted to the hospitalist service to rule out CVA  12/17/21: Possible TIA  - with gait instability. MRI brain: no acute infarct. Currently on aspirin and high-intensity statin.  No focal deficits appreciated during course of exam.  Patient appears to be baseline continue meds as ordered optimize blood pressures noted below.  COVID-19 infection  - with intermittent fever, but no respiratory symptoms. Continues to be on room air, remains afebrile for greater than 24 hours.  Mild leukopenia, trend.  Chest x-ray negative CRP 2.5.   Supportive measures currently. COVID-19 precautions to be provided for dispo.  suspected acute bronchitis: improved clinically  - did receive short course of antibiotics no coughing congestion or coarse sounds noted room air symptomatic management as noted will need to mobilize Acapella.  Uncontrolled hypertension: improved  - On  BP meds: Atenolol, Losartan, Isosorbide, Hydralazine.  Does periodically have some high readings, medications have been titrated.  Suspect may need further titration have strongly advised to follow-up with PCP within 7 days of discharge from skilled for further management titration of blood pressure.  chronic systolic dysfunction- CHF-not in acute exacerbation  - Echo: EF:35-45% On Atenolol and Losartan.  Continue monitor fluid status  Deconditioning with gait instability  PT/OT. social service for placement to SNF when bed is available    All ED in RTC precautions have been provided patient, she endorses understanding and is agreement with plan as outlined.  She patient will need to follow PCP within 7 days of discharge for longitudinal management.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Laboratory test normal, Leukopenia, Magnetic resonance imaging head normal, Muscular weakness, Physical deconditioning
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 2/23/21 (EN6200) Pfizer Dose 2 3/17/21 (EN6204) COVID Positive 12/7/21 COVID Positive 12/16/21  12/7/21: A 90-year-old woman with a history of hypertension, colonic diverticulosis who presented to the emergency room with complains left-sided facial facial droop and weakness which was noticed today.  Family had noted weakness in the right upper extremity.  No prior history of stroke.  No history of coronary artery disease. No loss of consciousness.  On presentation to the emergency room, vital signs revealed elevated blood pressure with systolic of 184/80 mmHg.  Laboratory workup is unremarkable.  EKG done reveals sinus rhythm with first-degree AV block with supraventricular complexes. Chest x-ray reveals no acute abnormality.  CT scan of the head does not reveal any acute intracranial process which shows bilateral chronic use to me changes.  In the emergency room patient received aspirin neurologist was consulted who recommended admission to the hospitalist service.  Patient is being admitted to the hospitalist service to rule out CVA  12/17/21: Possible TIA  - with gait instability. MRI brain: no acute infarct. Currently on aspirin and high-intensity statin.  No focal deficits appreciated during course of exam.  Patient appears to be baseline continue meds as ordered optimize blood pressures noted below.  COVID-19 infection  - with intermittent fever, but no respiratory symptoms. Continues to be on room air, remains afebrile for greater than 24 hours.  Mild leukopenia, trend.  Chest x-ray negative CRP 2.5.   Supportive measures currently. COVID-19 precautions to be provided for dispo.  suspected acute bronchitis: improved clinically  - did receive short course of antibiotics no coughing congestion or coarse sounds noted room air symptomatic management as noted will need to mobilize Acapella.  Uncontrolled hypertension: improved  - On  BP meds: Atenolol, Losartan, Isosorbide, Hydralazine.  Does periodically have some high readings, medications have been titrated.  Suspect may need further titration have strongly advised to follow-up with PCP within 7 days of discharge from skilled for further management titration of blood pressure.  chronic systolic dysfunction- CHF-not in acute exacerbation  - Echo: EF:35-45% On Atenolol and Losartan.  Continue monitor fluid status  Deconditioning with gait instability  PT/OT. social service for placement to SNF when bed is available    All ED in RTC precautions have been provided patient, she endorses understanding and is agreement with plan as outlined.  She patient will need to follow PCP within 7 days of discharge for longitudinal management.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive, Sinus rhythm, Supraventricular tachycardia, Systolic dysfunction
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 2/23/21 (EN6200) Pfizer Dose 2 3/17/21 (EN6204) COVID Positive 12/7/21 COVID Positive 12/16/21  12/7/21: A 90-year-old woman with a history of hypertension, colonic diverticulosis who presented to the emergency room with complains left-sided facial facial droop and weakness which was noticed today.  Family had noted weakness in the right upper extremity.  No prior history of stroke.  No history of coronary artery disease. No loss of consciousness.  On presentation to the emergency room, vital signs revealed elevated blood pressure with systolic of 184/80 mmHg.  Laboratory workup is unremarkable.  EKG done reveals sinus rhythm with first-degree AV block with supraventricular complexes. Chest x-ray reveals no acute abnormality.  CT scan of the head does not reveal any acute intracranial process which shows bilateral chronic use to me changes.  In the emergency room patient received aspirin neurologist was consulted who recommended admission to the hospitalist service.  Patient is being admitted to the hospitalist service to rule out CVA  12/17/21: Possible TIA  - with gait instability. MRI brain: no acute infarct. Currently on aspirin and high-intensity statin.  No focal deficits appreciated during course of exam.  Patient appears to be baseline continue meds as ordered optimize blood pressures noted below.  COVID-19 infection  - with intermittent fever, but no respiratory symptoms. Continues to be on room air, remains afebrile for greater than 24 hours.  Mild leukopenia, trend.  Chest x-ray negative CRP 2.5.   Supportive measures currently. COVID-19 precautions to be provided for dispo.  suspected acute bronchitis: improved clinically  - did receive short course of antibiotics no coughing congestion or coarse sounds noted room air symptomatic management as noted will need to mobilize Acapella.  Uncontrolled hypertension: improved  - On  BP meds: Atenolol, Losartan, Isosorbide, Hydralazine.  Does periodically have some high readings, medications have been titrated.  Suspect may need further titration have strongly advised to follow-up with PCP within 7 days of discharge from skilled for further management titration of blood pressure.  chronic systolic dysfunction- CHF-not in acute exacerbation  - Echo: EF:35-45% On Atenolol and Losartan.  Continue monitor fluid status  Deconditioning with gait instability  PT/OT. social service for placement to SNF when bed is available    All ED in RTC precautions have been provided patient, she endorses understanding and is agreement with plan as outlined.  She patient will need to follow PCP within 7 days of discharge for longitudinal management.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccine breakthrough infection
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 2/23/21 (EN6200) Pfizer Dose 2 3/17/21 (EN6204) COVID Positive 12/7/21 COVID Positive 12/16/21  12/7/21: A 90-year-old woman with a history of hypertension, colonic diverticulosis who presented to the emergency room with complains left-sided facial facial droop and weakness which was noticed today.  Family had noted weakness in the right upper extremity.  No prior history of stroke.  No history of coronary artery disease. No loss of consciousness.  On presentation to the emergency room, vital signs revealed elevated blood pressure with systolic of 184/80 mmHg.  Laboratory workup is unremarkable.  EKG done reveals sinus rhythm with first-degree AV block with supraventricular complexes. Chest x-ray reveals no acute abnormality.  CT scan of the head does not reveal any acute intracranial process which shows bilateral chronic use to me changes.  In the emergency room patient received aspirin neurologist was consulted who recommended admission to the hospitalist service.  Patient is being admitted to the hospitalist service to rule out CVA  12/17/21: Possible TIA  - with gait instability. MRI brain: no acute infarct. Currently on aspirin and high-intensity statin.  No focal deficits appreciated during course of exam.  Patient appears to be baseline continue meds as ordered optimize blood pressures noted below.  COVID-19 infection  - with intermittent fever, but no respiratory symptoms. Continues to be on room air, remains afebrile for greater than 24 hours.  Mild leukopenia, trend.  Chest x-ray negative CRP 2.5.   Supportive measures currently. COVID-19 precautions to be provided for dispo.  suspected acute bronchitis: improved clinically  - did receive short course of antibiotics no coughing congestion or coarse sounds noted room air symptomatic management as noted will need to mobilize Acapella.  Uncontrolled hypertension: improved  - On  BP meds: Atenolol, Losartan, Isosorbide, Hydralazine.  Does periodically have some high readings, medications have been titrated.  Suspect may need further titration have strongly advised to follow-up with PCP within 7 days of discharge from skilled for further management titration of blood pressure.  chronic systolic dysfunction- CHF-not in acute exacerbation  - Echo: EF:35-45% On Atenolol and Losartan.  Continue monitor fluid status  Deconditioning with gait instability  PT/OT. social service for placement to SNF when bed is available    All ED in RTC precautions have been provided patient, she endorses understanding and is agreement with plan as outlined.  She patient will need to follow PCP within 7 days of discharge for longitudinal management.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acute left ventricular failure, COVID-19, Cardiac failure congestive, Ejection fraction decreased, SARS-CoV-2 test positive
Clinical narrative: Pt was admitted for acute systolic CHF with an EF of 20 to 25% and has a life vest.  The pt was scheduled for a TAVR at the facility on May 19.  Prior to transfer to the facility he was tested for COVID and was positive with a CT value of 39.1.  He was previously positive for COVID in December 2021.
Age: 76.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Transcatheter aortic valve implantation
Clinical narrative: Pt was admitted for acute systolic CHF with an EF of 20 to 25% and has a life vest.  The pt was scheduled for a TAVR at the facility on May 19.  Prior to transfer to the facility he was tested for COVID and was positive with a CT value of 39.1.  He was previously positive for COVID in December 2021.
Age: 66.0
Sex: U
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 19.0
Sex: M
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: vaccines where not stored at correct temperature they had been stored in freezer instead of refrigerator
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, COVID-19, Condition aggravated, Fatigue, Irritable bowel syndrome
Clinical narrative: It started with low energy and a severe sore throat. I took a home COVID-19 test and it was negative. I went to our local hospital and took one of their tests and found out that night it was positive. The next night, I still had a really bad sore throat and a fever of 100.4. I was also very fatigued. I took a five day course of the generic version of Paxlovid. By 04/25/2022 I felt better but the fatigue stuck with me for about 10 days. I was still testing positive for about nine or ten days. During the days I am able to do normal activities but at night I still get very fatigued around 9pm. Also, about a week after I started feeling back to normal, I had an really bad IBS flare up that last about 5 days.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Pyrexia, SARS-CoV-2 test positive
Clinical narrative: It started with low energy and a severe sore throat. I took a home COVID-19 test and it was negative. I went to our local hospital and took one of their tests and found out that night it was positive. The next night, I still had a really bad sore throat and a fever of 100.4. I was also very fatigued. I took a five day course of the generic version of Paxlovid. By 04/25/2022 I felt better but the fatigue stuck with me for about 10 days. I was still testing positive for about nine or ten days. During the days I am able to do normal activities but at night I still get very fatigued around 9pm. Also, about a week after I started feeling back to normal, I had an really bad IBS flare up that last about 5 days.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Asthenia, Blood sodium decreased, COVID-19, Chest X-ray abnormal
Clinical narrative: COVID Vaccine Breakthrough Case  J&J Dose 2/2/21 (1855194) COVID Positive 12/15/21  12/15/21: 58-year-old male with no past medical history except he has a chronic smoker.  He presented to the emergency room this morning complaining of worsening SOB and associated cough of 5 days duration.  He also complained of fever, nausea, occasional vomiting, generalized weakness and some myalgia.  Patient received 1 dose of Johnson and Johnson COVID vaccine on 12/02/2021. At the emergency room he was quite febrile with a temperature of 104.2° F and hypoxic currently requiring 3-4 L of oxygen with O2 saturation of 100% but on room air saturation is 88%.  Other vitals are normal.  The laboratory test is significant for mild hyponatremia with Na 132 and D-dimer of 0.77.  CT angiogram of the chest revealed no PE in the proximal vessels, mediastinal, bilateral hilar adenopathy and bilateral infiltrates right greater than left.  12/18/21: 58-year-old man who presented worsening shortness of breath, cough for 5 days duration.  In the emergency department he was noted to be febrile and hypoxic on room air, COVID-19 rapid antigen and PCR was subsequently positive.  Chest x-ray   And CT pulmonary angiogram demonstrated bilateral viral pneumonitis and ruled out pulmonary embolism.  was admitted to the hospitalist service where was started on anti-inflammatory agents, parenteral steroids and remdesivir with good effect.  Clinical response was favorable with resolution of hypoxia, improvement in shortness of breath and cough.  He has been successfully weaned to room air will be discharged today in stable medical condition to continue outpatient follow-up.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Cough, Dyspnoea, Fibrin D dimer, Hilar lymphadenopathy, Hyponatraemia
Clinical narrative: COVID Vaccine Breakthrough Case  J&J Dose 2/2/21 (1855194) COVID Positive 12/15/21  12/15/21: 58-year-old male with no past medical history except he has a chronic smoker.  He presented to the emergency room this morning complaining of worsening SOB and associated cough of 5 days duration.  He also complained of fever, nausea, occasional vomiting, generalized weakness and some myalgia.  Patient received 1 dose of Johnson and Johnson COVID vaccine on 12/02/2021. At the emergency room he was quite febrile with a temperature of 104.2° F and hypoxic currently requiring 3-4 L of oxygen with O2 saturation of 100% but on room air saturation is 88%.  Other vitals are normal.  The laboratory test is significant for mild hyponatremia with Na 132 and D-dimer of 0.77.  CT angiogram of the chest revealed no PE in the proximal vessels, mediastinal, bilateral hilar adenopathy and bilateral infiltrates right greater than left.  12/18/21: 58-year-old man who presented worsening shortness of breath, cough for 5 days duration.  In the emergency department he was noted to be febrile and hypoxic on room air, COVID-19 rapid antigen and PCR was subsequently positive.  Chest x-ray   And CT pulmonary angiogram demonstrated bilateral viral pneumonitis and ruled out pulmonary embolism.  was admitted to the hospitalist service where was started on anti-inflammatory agents, parenteral steroids and remdesivir with good effect.  Clinical response was favorable with resolution of hypoxia, improvement in shortness of breath and cough.  He has been successfully weaned to room air will be discharged today in stable medical condition to continue outpatient follow-up.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoxia, Laboratory test abnormal, Lung infiltration, Myalgia, Nausea
Clinical narrative: COVID Vaccine Breakthrough Case  J&J Dose 2/2/21 (1855194) COVID Positive 12/15/21  12/15/21: 58-year-old male with no past medical history except he has a chronic smoker.  He presented to the emergency room this morning complaining of worsening SOB and associated cough of 5 days duration.  He also complained of fever, nausea, occasional vomiting, generalized weakness and some myalgia.  Patient received 1 dose of Johnson and Johnson COVID vaccine on 12/02/2021. At the emergency room he was quite febrile with a temperature of 104.2° F and hypoxic currently requiring 3-4 L of oxygen with O2 saturation of 100% but on room air saturation is 88%.  Other vitals are normal.  The laboratory test is significant for mild hyponatremia with Na 132 and D-dimer of 0.77.  CT angiogram of the chest revealed no PE in the proximal vessels, mediastinal, bilateral hilar adenopathy and bilateral infiltrates right greater than left.  12/18/21: 58-year-old man who presented worsening shortness of breath, cough for 5 days duration.  In the emergency department he was noted to be febrile and hypoxic on room air, COVID-19 rapid antigen and PCR was subsequently positive.  Chest x-ray   And CT pulmonary angiogram demonstrated bilateral viral pneumonitis and ruled out pulmonary embolism.  was admitted to the hospitalist service where was started on anti-inflammatory agents, parenteral steroids and remdesivir with good effect.  Clinical response was favorable with resolution of hypoxia, improvement in shortness of breath and cough.  He has been successfully weaned to room air will be discharged today in stable medical condition to continue outpatient follow-up.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Pneumonia, Pneumonia viral, Pyrexia, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: COVID Vaccine Breakthrough Case  J&J Dose 2/2/21 (1855194) COVID Positive 12/15/21  12/15/21: 58-year-old male with no past medical history except he has a chronic smoker.  He presented to the emergency room this morning complaining of worsening SOB and associated cough of 5 days duration.  He also complained of fever, nausea, occasional vomiting, generalized weakness and some myalgia.  Patient received 1 dose of Johnson and Johnson COVID vaccine on 12/02/2021. At the emergency room he was quite febrile with a temperature of 104.2° F and hypoxic currently requiring 3-4 L of oxygen with O2 saturation of 100% but on room air saturation is 88%.  Other vitals are normal.  The laboratory test is significant for mild hyponatremia with Na 132 and D-dimer of 0.77.  CT angiogram of the chest revealed no PE in the proximal vessels, mediastinal, bilateral hilar adenopathy and bilateral infiltrates right greater than left.  12/18/21: 58-year-old man who presented worsening shortness of breath, cough for 5 days duration.  In the emergency department he was noted to be febrile and hypoxic on room air, COVID-19 rapid antigen and PCR was subsequently positive.  Chest x-ray   And CT pulmonary angiogram demonstrated bilateral viral pneumonitis and ruled out pulmonary embolism.  was admitted to the hospitalist service where was started on anti-inflammatory agents, parenteral steroids and remdesivir with good effect.  Clinical response was favorable with resolution of hypoxia, improvement in shortness of breath and cough.  He has been successfully weaned to room air will be discharged today in stable medical condition to continue outpatient follow-up.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Vomiting
Clinical narrative: COVID Vaccine Breakthrough Case  J&J Dose 2/2/21 (1855194) COVID Positive 12/15/21  12/15/21: 58-year-old male with no past medical history except he has a chronic smoker.  He presented to the emergency room this morning complaining of worsening SOB and associated cough of 5 days duration.  He also complained of fever, nausea, occasional vomiting, generalized weakness and some myalgia.  Patient received 1 dose of Johnson and Johnson COVID vaccine on 12/02/2021. At the emergency room he was quite febrile with a temperature of 104.2° F and hypoxic currently requiring 3-4 L of oxygen with O2 saturation of 100% but on room air saturation is 88%.  Other vitals are normal.  The laboratory test is significant for mild hyponatremia with Na 132 and D-dimer of 0.77.  CT angiogram of the chest revealed no PE in the proximal vessels, mediastinal, bilateral hilar adenopathy and bilateral infiltrates right greater than left.  12/18/21: 58-year-old man who presented worsening shortness of breath, cough for 5 days duration.  In the emergency department he was noted to be febrile and hypoxic on room air, COVID-19 rapid antigen and PCR was subsequently positive.  Chest x-ray   And CT pulmonary angiogram demonstrated bilateral viral pneumonitis and ruled out pulmonary embolism.  was admitted to the hospitalist service where was started on anti-inflammatory agents, parenteral steroids and remdesivir with good effect.  Clinical response was favorable with resolution of hypoxia, improvement in shortness of breath and cough.  He has been successfully weaned to room air will be discharged today in stable medical condition to continue outpatient follow-up.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: Anosmia, Olfactory test abnormal
Clinical narrative: I noticed that for at least a year I had been losing my smell. My son inquired about my sense of smell and taste. I scheduled an appointment with my doctor. I took a test of 40 different smells and failed. I got 11 of them correct out of 40. I am doing olfactory training where I sniff common smells. The doctor provided all types of information on how to proceed. The doctor scheduled me for an MRI in a few weeks.
Age: 65.0
Sex: M
Vaccine: COVID19
Symptoms: Vision blurred
Clinical narrative: left eye became blurry  all of sudden , went to see Dr - opthalmalogist, NOthing seen on exam,  As of today, blurriness has improved but has not gone away.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Neuralgia
Clinical narrative: Lower back pain not muscular more nerve type.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Acute respiratory failure, Asthenia, COVID-19, COVID-19 pneumonia, Chest tube insertion
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/7/21 (lot NA) Pfizer Dose 2 5/5/21 (lot NA) COVID Positive 11/17/21  11/17/21: Patient is a 65 year old female with past history of diabetes mellitus, obesity, and depression who was admitted with respiratory failure secondary to COVID-19 pneumonia.  History is obtained from chart review as well as discussion with the patient and the outside hospitalist. Patient denies any underlying history of heart or lung disease.  She does not using inhalers.  She started feeling poorly approximately 2 weeks ago.  Has had fatigue and weakness and then started developing a cough with chest congestion about 5 days ago.  She then started becoming more short of breath over last few days as well.  She is not having any nausea or vomiting or diarrhea but does admit to a decreased appetite.  She presented to the ER yesterday after her daughter checked her pulse ox and was found to be 67% on room air.  She was placed on 2 L and admitted to that hospital.  She does state that she received 2 doses of the Pfizer COVID-19 vaccine.  Oxygen requirements increased overnight and was transferred to this facility for higher level of care.  Was on 15 L earlier today but currently on 10 L. She states she does have obstructive sleep apnea for which she uses a CPAP at night.  She was given remdesivir as well as Decadron and started on ceftriaxone and azithromycin.  She is currently afebrile.  She denies any chest pain or abdominal pain.  12/19/21: 65-year-old female with obstructive sleep apnea on CPAP, cirrhosis with esophageal varices, type 2 diabetes mellitus, hypertension admitted for acute hypoxemic respiratory failure secondary to COVID-19 and pneumonia. Patient was treated with remdesivir, Decadron, Actemra, broad-spectrum antibiotics.  Patient's oxygen requirement was persistently elevated with progressive worsening hypoxia and ended up intubated on 12/15/2021, developed right-sided pneumothorax pneumomediastinum and subcutaneous emphysema which was treated with chest tube.  Right-sided Pneumothorax has expanded, 2nd chest tube was placed with resolution of pneumothorax.  Patient's condition continued to deteriorate with persistent hypoxia despite being on full ventilator support with 100% FiO2.  Patient's family has decided on comfort care and care had been withdrawn and patient died on 12/19/2021 at 1642. Cause of death COVID 19.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Cough, Death, Decreased appetite, Dyspnoea, Endotracheal intubation
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/7/21 (lot NA) Pfizer Dose 2 5/5/21 (lot NA) COVID Positive 11/17/21  11/17/21: Patient is a 65 year old female with past history of diabetes mellitus, obesity, and depression who was admitted with respiratory failure secondary to COVID-19 pneumonia.  History is obtained from chart review as well as discussion with the patient and the outside hospitalist. Patient denies any underlying history of heart or lung disease.  She does not using inhalers.  She started feeling poorly approximately 2 weeks ago.  Has had fatigue and weakness and then started developing a cough with chest congestion about 5 days ago.  She then started becoming more short of breath over last few days as well.  She is not having any nausea or vomiting or diarrhea but does admit to a decreased appetite.  She presented to the ER yesterday after her daughter checked her pulse ox and was found to be 67% on room air.  She was placed on 2 L and admitted to that hospital.  She does state that she received 2 doses of the Pfizer COVID-19 vaccine.  Oxygen requirements increased overnight and was transferred to this facility for higher level of care.  Was on 15 L earlier today but currently on 10 L. She states she does have obstructive sleep apnea for which she uses a CPAP at night.  She was given remdesivir as well as Decadron and started on ceftriaxone and azithromycin.  She is currently afebrile.  She denies any chest pain or abdominal pain.  12/19/21: 65-year-old female with obstructive sleep apnea on CPAP, cirrhosis with esophageal varices, type 2 diabetes mellitus, hypertension admitted for acute hypoxemic respiratory failure secondary to COVID-19 and pneumonia. Patient was treated with remdesivir, Decadron, Actemra, broad-spectrum antibiotics.  Patient's oxygen requirement was persistently elevated with progressive worsening hypoxia and ended up intubated on 12/15/2021, developed right-sided pneumothorax pneumomediastinum and subcutaneous emphysema which was treated with chest tube.  Right-sided Pneumothorax has expanded, 2nd chest tube was placed with resolution of pneumothorax.  Patient's condition continued to deteriorate with persistent hypoxia despite being on full ventilator support with 100% FiO2.  Patient's family has decided on comfort care and care had been withdrawn and patient died on 12/19/2021 at 1642. Cause of death COVID 19.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Feeling abnormal, General physical health deterioration, Mechanical ventilation, Pneumomediastinum
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/7/21 (lot NA) Pfizer Dose 2 5/5/21 (lot NA) COVID Positive 11/17/21  11/17/21: Patient is a 65 year old female with past history of diabetes mellitus, obesity, and depression who was admitted with respiratory failure secondary to COVID-19 pneumonia.  History is obtained from chart review as well as discussion with the patient and the outside hospitalist. Patient denies any underlying history of heart or lung disease.  She does not using inhalers.  She started feeling poorly approximately 2 weeks ago.  Has had fatigue and weakness and then started developing a cough with chest congestion about 5 days ago.  She then started becoming more short of breath over last few days as well.  She is not having any nausea or vomiting or diarrhea but does admit to a decreased appetite.  She presented to the ER yesterday after her daughter checked her pulse ox and was found to be 67% on room air.  She was placed on 2 L and admitted to that hospital.  She does state that she received 2 doses of the Pfizer COVID-19 vaccine.  Oxygen requirements increased overnight and was transferred to this facility for higher level of care.  Was on 15 L earlier today but currently on 10 L. She states she does have obstructive sleep apnea for which she uses a CPAP at night.  She was given remdesivir as well as Decadron and started on ceftriaxone and azithromycin.  She is currently afebrile.  She denies any chest pain or abdominal pain.  12/19/21: 65-year-old female with obstructive sleep apnea on CPAP, cirrhosis with esophageal varices, type 2 diabetes mellitus, hypertension admitted for acute hypoxemic respiratory failure secondary to COVID-19 and pneumonia. Patient was treated with remdesivir, Decadron, Actemra, broad-spectrum antibiotics.  Patient's oxygen requirement was persistently elevated with progressive worsening hypoxia and ended up intubated on 12/15/2021, developed right-sided pneumothorax pneumomediastinum and subcutaneous emphysema which was treated with chest tube.  Right-sided Pneumothorax has expanded, 2nd chest tube was placed with resolution of pneumothorax.  Patient's condition continued to deteriorate with persistent hypoxia despite being on full ventilator support with 100% FiO2.  Patient's family has decided on comfort care and care had been withdrawn and patient died on 12/19/2021 at 1642. Cause of death COVID 19.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Pneumothorax, Respiratory failure, Respiratory tract congestion, SARS-CoV-2 test positive, Subcutaneous emphysema
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/7/21 (lot NA) Pfizer Dose 2 5/5/21 (lot NA) COVID Positive 11/17/21  11/17/21: Patient is a 65 year old female with past history of diabetes mellitus, obesity, and depression who was admitted with respiratory failure secondary to COVID-19 pneumonia.  History is obtained from chart review as well as discussion with the patient and the outside hospitalist. Patient denies any underlying history of heart or lung disease.  She does not using inhalers.  She started feeling poorly approximately 2 weeks ago.  Has had fatigue and weakness and then started developing a cough with chest congestion about 5 days ago.  She then started becoming more short of breath over last few days as well.  She is not having any nausea or vomiting or diarrhea but does admit to a decreased appetite.  She presented to the ER yesterday after her daughter checked her pulse ox and was found to be 67% on room air.  She was placed on 2 L and admitted to that hospital.  She does state that she received 2 doses of the Pfizer COVID-19 vaccine.  Oxygen requirements increased overnight and was transferred to this facility for higher level of care.  Was on 15 L earlier today but currently on 10 L. She states she does have obstructive sleep apnea for which she uses a CPAP at night.  She was given remdesivir as well as Decadron and started on ceftriaxone and azithromycin.  She is currently afebrile.  She denies any chest pain or abdominal pain.  12/19/21: 65-year-old female with obstructive sleep apnea on CPAP, cirrhosis with esophageal varices, type 2 diabetes mellitus, hypertension admitted for acute hypoxemic respiratory failure secondary to COVID-19 and pneumonia. Patient was treated with remdesivir, Decadron, Actemra, broad-spectrum antibiotics.  Patient's oxygen requirement was persistently elevated with progressive worsening hypoxia and ended up intubated on 12/15/2021, developed right-sided pneumothorax pneumomediastinum and subcutaneous emphysema which was treated with chest tube.  Right-sided Pneumothorax has expanded, 2nd chest tube was placed with resolution of pneumothorax.  Patient's condition continued to deteriorate with persistent hypoxia despite being on full ventilator support with 100% FiO2.  Patient's family has decided on comfort care and care had been withdrawn and patient died on 12/19/2021 at 1642. Cause of death COVID 19.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccine breakthrough infection
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 4/7/21 (lot NA) Pfizer Dose 2 5/5/21 (lot NA) COVID Positive 11/17/21  11/17/21: Patient is a 65 year old female with past history of diabetes mellitus, obesity, and depression who was admitted with respiratory failure secondary to COVID-19 pneumonia.  History is obtained from chart review as well as discussion with the patient and the outside hospitalist. Patient denies any underlying history of heart or lung disease.  She does not using inhalers.  She started feeling poorly approximately 2 weeks ago.  Has had fatigue and weakness and then started developing a cough with chest congestion about 5 days ago.  She then started becoming more short of breath over last few days as well.  She is not having any nausea or vomiting or diarrhea but does admit to a decreased appetite.  She presented to the ER yesterday after her daughter checked her pulse ox and was found to be 67% on room air.  She was placed on 2 L and admitted to that hospital.  She does state that she received 2 doses of the Pfizer COVID-19 vaccine.  Oxygen requirements increased overnight and was transferred to this facility for higher level of care.  Was on 15 L earlier today but currently on 10 L. She states she does have obstructive sleep apnea for which she uses a CPAP at night.  She was given remdesivir as well as Decadron and started on ceftriaxone and azithromycin.  She is currently afebrile.  She denies any chest pain or abdominal pain.  12/19/21: 65-year-old female with obstructive sleep apnea on CPAP, cirrhosis with esophageal varices, type 2 diabetes mellitus, hypertension admitted for acute hypoxemic respiratory failure secondary to COVID-19 and pneumonia. Patient was treated with remdesivir, Decadron, Actemra, broad-spectrum antibiotics.  Patient's oxygen requirement was persistently elevated with progressive worsening hypoxia and ended up intubated on 12/15/2021, developed right-sided pneumothorax pneumomediastinum and subcutaneous emphysema which was treated with chest tube.  Right-sided Pneumothorax has expanded, 2nd chest tube was placed with resolution of pneumothorax.  Patient's condition continued to deteriorate with persistent hypoxia despite being on full ventilator support with 100% FiO2.  Patient's family has decided on comfort care and care had been withdrawn and patient died on 12/19/2021 at 1642. Cause of death COVID 19.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Dysphonia, Feeling abnormal, Loss of personal independence in daily activities, Respiratory tract congestion
Clinical narrative: *********************COVID BREAKTHROUGH CASE******************** On 05/18 in the afternoon, I started feeling congestion and having a gravelly voice and 5/19 I felt pretty miserable in the morning unable to do my normal activated because I felt so bad so I returned home and took the at home test and it was positive I had chills and a high temperature body aches headache chills and fatigue 103.2 was the highest temp I had Called my doctor to inform them and then they called back with instructions to take Tylenol as needed not over 600 per dose and Mucinex and to coronatine and stay hydrated and get penalty of rest. It felt like a bad case of the flu.
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Vaccine breakthrough infection
Clinical narrative: *********************COVID BREAKTHROUGH CASE******************** On 05/18 in the afternoon, I started feeling congestion and having a gravelly voice and 5/19 I felt pretty miserable in the morning unable to do my normal activated because I felt so bad so I returned home and took the at home test and it was positive I had chills and a high temperature body aches headache chills and fatigue 103.2 was the highest temp I had Called my doctor to inform them and then they called back with instructions to take Tylenol as needed not over 600 per dose and Mucinex and to coronatine and stay hydrated and get penalty of rest. It felt like a bad case of the flu.
Age: 18.0
Sex: F
Vaccine: COVID19
Symptoms: Product storage error
Clinical narrative: vaccines where not stored at correct temperature they had been stored in freezer instead of refrigerator
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Angiogram pulmonary abnormal, Anion gap, Asthenia, Blood creatinine increased, Blood glucose normal
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/10/21 (EN6203) Pfizer Dose 2 4/2/21 (ER8734) COVID Positive 12/1/21  12/1/21:  Patient is 90-year-old female past medical history significant for essential hypertension, hyperlipidemia, obesity, chronic cough  Patient presented with generalized weakness and cough of 2 days duration.  Patient progressively started to feel much worse with worsening of cough; has been vaccinated for COVID but has contact with family members having coli 19 infection.  Patient rapid test for COVID at with compass was negative.  In the emergency room patient was febrile tachypneic and tachycardic and was requiring oxygen supplementation 7 LPM than 15 liter/minute; had to be transition to BiPAP after which saturation improved.  Lab was significant for hyponatremia of 132; anion gap of 17 with elevated glucose of 121; creatinine was elevated 1.02.  And proBNP was also elevated 6622 with elevated troponin of 1.05.  Cell count showed thrombocytopenia of 118 with lymphopenia; D-dimer was also elevated 1.31.  Portable chest x-ray shows scattered bilateral area of airspace disease likely representing multilobar pneumonia or viral pneumonitis  CT angio of the chest was unremarkable for pulmonary embolism; however showed scattered bilateral area of airspace disease likely representing viral pneumonitis or multilobar pneumonia  12/22/21: 90-year-old woman who presented emergency department with generalized weakness, fever and malaise following exposure to a COVID best if individual.  COVID post 19 PCR was noted to be positive, she was hypoxic requiring initiation of supplemental oxygen.  She was admitted to the hospitalist service where progressive increasing oxygen requirements was noted despite treatment with IV remdesivir, Actemra, steroids, empiric antibiotic therapy.  She was transferred to the intensive care unit where she was managed with high-flow oxygen and BiPAP, also required brief period of pressor support on account of hypotension.  Subsequent improvement noted in oxygen requirements and she did not require intubation, she was then transferred to the floor she has gradually been weaned down from high-flow oxygen down to 5 liters/minutes of supplemental oxygen via nasal cannula at the time of discharge.  She is in fair medical condition and has been discharged to skilled nursing facility for continued rehabilitation.
Age: 89.0
Sex: F
Vaccine: COVID19
Symptoms: Blood sodium decreased, COVID-19, Chest X-ray abnormal, Cough, Exposure to SARS-CoV-2
Clinical narrative: COVID Vaccine Breakthrough Case  Pfizer Dose 1 3/10/21 (EN6203) Pfizer Dose 2 4/2/21 (ER8734) COVID Positive 12/1/21  12/1/21:  Patient is 90-year-old female past medical history significant for essential hypertension, hyperlipidemia, obesity, chronic cough  Patient presented with generalized weakness and cough of 2 days duration.  Patient progressively started to feel much worse with worsening of cough; has been vaccinated for COVID but has contact with family members having coli 19 infection.  Patient rapid test for COVID at with compass was negative.  In the emergency room patient was febrile tachypneic and tachycardic and was requiring oxygen supplementation 7 LPM than 15 liter/minute; had to be transition to BiPAP after which saturation improved.  Lab was significant for hyponatremia of 132; anion gap of 17 with elevated glucose of 121; creatinine was elevated 1.02.  And proBNP was also elevated 6622 with elevated troponin of 1.05.  Cell count showed thrombocytopenia of 118 with lymphopenia; D-dimer was also elevated 1.31.  Portable chest x-ray shows scattered bilateral area of airspace disease likely representing multilobar pneumonia or viral pneumonitis  CT angio of the chest was unremarkable for pulmonary embolism; however showed scattered bilateral area of airspace disease likely representing viral pneumonitis or multilobar pneumonia  12/22/21: 90-year-old woman who presented emergency department with generalized weakness, fever and malaise following exposure to a COVID best if individual.  COVID post 19 PCR was noted to be positive, she was hypoxic requiring initiation of supplemental oxygen.  She was admitted to the hospitalist service where progressive increasing oxygen requirements was noted despite treatment with IV remdesivir, Actemra, steroids, empiric antibiotic therapy.  She was transferred to the intensive care unit where she was managed with high-flow oxygen and BiPAP, also required brief period of pressor support on account of hypotension.  Subsequent improvement noted in oxygen requirements and she did not require intubation, she was then transferred to the floor she has gradually been weaned down from high-flow oxygen down to 5 liters/minutes of supplemental oxygen via nasal cannula at the time of discharge.  She is in fair medical condition and has been discharged to skilled nursing facility for continued rehabilitation.